Mycenax Biotech Profit Margin

The latest profit margin for 4726.TWO is -46.81% as of June 2026. That compares with -68.22% in the prior-year period — up 31.4% year over year. That is below the Healthcare sector average of 9.71%. Investors often review this figure alongside Mycenax Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4726.TWO's profit margin moved from -68.22% to -46.81% — a 31.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mycenax Biotech's valuation or profitability profile.

Against Healthcare companies, 4726.TWO currently prints -46.81% for profit margin, while the sector average sits near 9.71%. That is roughly 582.3% below the sector mean. Large gaps often invite a closer look at Mycenax Biotech's growth, margins, and balance sheet.

Profit Margin shows how effectively Mycenax Biotech converts resources into returns. At -46.81%, 4726.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -68.22% in the prior-year period — up 31.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 4726.TWO's profit margin (-46.81%), review year-over-year change from -68.22%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.